Three groups of countries to adopt the implementation of the program and rules at the end of July, the selection rules change dischanged or not change?

Author. Code Wanxuan recently, the network on the third batch of national collection of the meeting held in Shanghai.
it is understood that the third batch of volume procurement rules have been basically finalized, is expected to open on August 18, the end of July will be issued implementation plans and rules.
the rules governing the selection are basically the same as those of the second batch of countries, using a 1.8-fold fuse mechanism and a 50 per cent reduction in prices.
(what is the final content, of course, subject to the official announcement). On July 21,
, Shanghai Sunshine Pharmaceutical Procurement Network issued a "Notice on the collection of basic information related to some drugs", introducing 86 standard drug collection related information.
notice indicates that the information collection work is only used for related work exploration and analysis research, not as the basis for the declaration of drug centralized procurement enterprises, the specific declaration of enterprise qualifications and the declaration of varieties of eligibility to the procurement documents.
" according to the network public data show that 86 product regulations in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 56 billion yuan, involving a total of 300 pharmaceutical companies.
the third round of collection varieties, China Biopharmaceuticalled led by 9 over-rated varieties; Qilu Pharmaceuticals, Haussen Pharmaceuticals, Hengrui Pharmaceuticals, Shi Pharmaceutical Group and other 4 enterprises involved in the number of varieties reached 6;
Huahai Pharmaceuticals and a group of competitors hold three over-rated varieties involved, it is not obvious.
": If "the third batch and the second batch of winning rules are basically the same" first, this to a certain extent means that the reform mature stereotypes, at least in the third batch of decision-making on the second batch of winning and losing (pattern, effect) is more recognized;
from the strategy, in fact, it is long overdue to give up the illusion, the overall promotion of centralized procurement is the set-up;
for example: we in the second batch of drug country picks saw Zhengda Qing refused to renew the contract of Entikawe, see The Zilu albumin yew alcohol selection, etc. , which in fact reflects the enterprise's own choice.
on the one hand, the supply market competition is more diversified, on the other hand, it also allows enterprises to have trade-offs.
looking at the future situation of drug-belt procurement, we need to think: First, the pattern of tape procurement accounted for the full amount of collection.
1, the focus is not only in generic drugs, chemical drugs, may affect biological similar drugs, traditional Chinese medicine, etc. , until including biological products, Chinese medicine, etc. ;
is in addition to the volume of procurement, there are also collection tools (such as GPO, price limit hanging network, direct hanging network, record procurement innovation, etc.), and the amount of procurement rules after the moderate training of how to remove some excessive administrative (if any) problems.
if the third batch of winning rules and the second batch are close to the same, perhaps revealed to move forward in this direction: that is, respect for the "quantitative price hook" principle under the existing market competition performance, continue to use the form of volume procurement to find new, fast-landing trading prices, stirring new drug reform.
corporate transformation: either the drug "group magic dance" or their own lonely from the corporate point of view.
is mainly "1.8 times the fuse mechanism and 50% price reduction", respectively, to limit the price range and the price reduction range.
we first look at the rationality: First, the third batch is the expansion of varieties, the number is still limited (dozens), and the standard conditions do not seem to be reduced (several over-reviews), next to the second batch in doing, the supply of competitive patternand demand efficiency purposes are close to the same, the principle is similar and reasonable.
It's not surprising if the next fourth and fifth batch is still at that pace.
secondly, the volume procurement in the centralized procurement of chemical generic drugs, in the centralized procurement of all drugs have been accounted for, will account for the proportion of a certain period of time by the impact of technical restrictions, each band purchase for each shortlisted variety only forced a certain proportion of the agreed procurement volume.
it is not surprising that if a business refuses to bid and instead competes for the remaining market and the off-court market.
at present, the volume of procurement and admission between the hospital is drawing more equal signs, the defeated drugs in the collection of stable prices outside the double-loneliness.
" July 20, Shaanxi Province issued the "Shanxi Province Public Resources Trading Center drug sunshine network dynamic adjustment implementation plan", will focus on the hanging network product prices dynamic adjustment, after the adjustment, dynamic adjustment work will enter the normal.
proposed to explore the establishment of low-cost drugs based on independent quotations of the price-limiting network system, the procurement of high-value, high-use drugs to carry out volume procurement or multi-participation price negotiations, to encourage private medical institutions enjoying the medical insurance reimbursement policy to participate in the drug sunshine procurement. On July 20,
, Jiangxi Province issued a notice announcing the standard of payment for health insurance for some generic drugs (including biosimilars) in 18 countries.
" on the out-of-hospital market, that is, the prescription outflow of the market, in the comprehensive medical reform, should also jump out of the "quantitative price-linked" collection principle, pay attention to the health insurance gradually unified payment standards of reform lethality.
at present, on the one hand is the chain of retail pharmacies, e-commerce drugs, DTP pharmacy volume and share growth is dazzling, on the other hand, more and more To patients' sales terminals and health insurance payment cooperation, affected by the health insurance payment policy.
comprehensive medical reform adheres to the people's interests as the center, the process and results of prescription outflow will inevitably reflect the effectiveness of drug price reform.
of this, we believe that: the volume of procurement of chemical genericdrugs, public hospitals clinical guarantee of the use of the two breakthroughs on the specific work, these two work to maintain the rhythm, efficiency, do not worry about other centralized procurement methods, the efficiency of other medical and health institutions temporarily still in a backward position, may lead the entire pharmaceutical market efficiency reform small step run, and may achieve the pharmaceutical industry supply-side production and research structure upgrade of the "cage for birds."
.